ECP FAQ

MacuMira uses a patented form of low-level current (microcurrent) delivered via contoured eye cups, which are integrated into a headset and gently rest on the closed eyelids.

These currents stimulate retinal RPE cells, enhancing mitochondrial activity to support cellular energy production and preserve/improve visual function.

Yes, MacuMira is supported by a clinical trial.

In a prospective clinical study involving patients with baseline visual acuity between 20/50 and 20/200, all treated patients experienced measurable visual gains. 48% of participants gained 10 or more letters on the ETDRS chart following a 4-week MacuMira stimulation treatment protocol, and the average improvement was over 8 letters.

Meanwhile, the placebo group’s visual acuity decreased by an average of 2 letters read.
These improvements were maintained over the 30-week follow-up period and were accompanied by enhancements in contrast sensitivity and patient-reported quality of life. The treatment was well tolerated, with no adverse events reported.

In addition to clinical data, MacuMira has been in use in clinical settings for over a year with an excellent safety profile across thousands of treatment sessions.

Additional clinical studies are underway or in the planning phase in support of ongoing research and indication expansion.

MacuMira is a truly unique dry AMD treatment.

It’s noninvasive, does not involve pharmaceuticals or neutraceuticals.

MacuMira uses microcurrent neurostimulation through proprietary eye cup delivery, offering a distinct mechanism targeting neuroretinal activation.

MacuMira has been shown in a clinical study to improve visual function in patients with dry AMD. This represents a different therapeutic approach than nutraceuticals like AREDS, which are designed to help slow disease progression.

MacuMira is intended for patients who have been diagnosed with dry age-related macular degeneration and are experiencing associated visual impairment. It is especially appropriate for people seeking a noninvasive treatment option to help preserve or improve their functional vision.

Yes, MacuMira can be safely used alongside AREDS supplements, low vision aids, and lifestyle modifications. It’s not intended to replace medical therapies for wet AMD.

Implementing MacuMira is straightforward and requires very minimal disruption to existing clinic operations.

Staff are trained to administer treatments in a single training session. There is no need for specialized certification or clinical supervision.

The device is compact and portable, allowing patients to be treated comfortably in any standard exam room or treatment area.

Most clinics are able to integrate MacuMira into their workflow with ease, often launching the same week after onboarding.

The MacuMira team supports clinics throughout the onboarding process as well as afterwards on an ongoing basis. We’re in this together.

Currently, MacuMira is not reimbursed through public or private insurance in most jurisdictions. However, some patients can claim it under Health Spending Accounts or medical expense tax credits.

Yes, MacuMira is a noninvasive treatment that has demonstrated a strong safety profile in both clinical studies and real-world use.

It has undergone rigorous safety review and licensing by Health Canada and meets the standards required of Class II medical devices.

The stimulation uses microcurrent levels that are incapable of causing muscle contraction and remain well below thresholds associated with discomfort or tissue damage. No adverse events were reported in the prospective clinical study, and the treatment has now been used in clinical settings for over a year with excellent tolerability across thousands of treatment sessions.

Patients typically find the treatment comfortable and easy to complete.